MUMBAI, India, September 12 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for generic Fosamax (R), alendronate sodium tablets.
Alendronate sodium tablets are indicated for the treatment and prevention of osteoporosis in post menopausal women, to increase bone mass in men with osteoporosis, in the treatment of glucocorticoid induced osteoporosis, and Paget's disease of the bone in men and women.
These generic versions of alendronate sodium tablets 5 mg (base), 10 mg (base), 35 mg (base) and 70 mg (base) are bio-equivalent to Fosamax (R) tablets distributed by Merck & Co.